These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32135516)

  • 1. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival.
    Everest L; Blommaert S; Chu RW; Chan KKW; Parmar A
    Value Health; 2022 Apr; 25(4):622-629. PubMed ID: 35365306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Mauro E; Sanduzzi-Zamparelli M; Sauri T; Soler A; Iserte G; Fortuny M; Forner A
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
    Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
    JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
    Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
    Oncologist; 2019 Nov; 24(11):1469-1478. PubMed ID: 31320502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.
    Leung TH; Ho JC; Wang X; Pang H
    Chin Clin Oncol; 2023 Oct; 12(5):53. PubMed ID: 37817506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
    Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
    Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
    Tan A; Porcher R; Crequit P; Ravaud P; Dechartres A
    J Clin Oncol; 2017 May; 35(15):1686-1694. PubMed ID: 28375786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis.
    Daly CH; Maconachie R; Ades AE; Welton NJ
    Res Synth Methods; 2022 Sep; 13(5):573-584. PubMed ID: 34898019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.
    Nocera L; Fallara G; Raggi D; Belladelli F; Robesti D; Montorsi F; Karakiewicz PI; Malavaud B; Ploussard G; Necchi A; Martini A
    Front Oncol; 2022; 12():955894. PubMed ID: 36132135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusting for covariates in analysis based on restricted mean survival times.
    Zhong Y; Zhao O; Zhang B; Yao B
    Pharm Stat; 2022 Jan; 21(1):38-54. PubMed ID: 34231308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.